Brief: EMA's CHMP Recommended Granting A Marketing Authorisation For Mcombriax
27/02/2026 11:17
Feb 27 (Reuters) - EMA's CHMP: EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR MCOMBRIAX EMA'S CHMP: COMMITTEE ADOPTED A POSITIVE OPINION FOR RHAPSIDO EMA'S CHMP: COMMITTEE RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR DAYBU (TROFINETIDE) EMA'S CHMP: ILOPERIDONE VANDA PHARMACEUTICALS (ILOPERIDONE) RECEIVED NEGATIVE OPINION FROM CHMP FOR TREATMENT OF SCHIZOPHRENIA EMA'S CHMP: COMMITTEE ADOPTED A POSITIVE OPINION FOR ACOZIBOROLE WINTHROP EMA'S CHMP: COMMITTEE RECOMMENDED TO EXTEND USE OF DUPIXENT (DUPILUMAB), FOR TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN CHILDREN AGED 2 TO 11 YRS
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)